A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial - Soo, R A; Vervita, K; Fruh, M; Cho, B C; Majem, M; Abreu, D Rodriguez; Ribi, K; Callejo, A; Moran, T; Gomez, M Domine; Provencio, M; Addeo, A; et al. (Lung Cancer, 2025)